Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting

30 Apr 2021

Leuven, BE, Boston, MA, US – April 30st, 2021 – 7.30 AM CET Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies with a clinical stage portfolio in retinal vascular disorders. Oxurion NV is announcing the presentation of novel scientific data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting which is held on May 1-7, 2021. 

Professor Alan Stitt, Ph.D., CSO at Oxurion NV comments: “We are happy to present these scientific findings at the ARVO 2021 annual meeting. A deep understanding of the cellular and molecular mechanisms that underpin retinal disease and the use of relevant preclinical models are instrumental for developing novel therapeutics. We are happy to share our insights with the global vision research community and mutually strengthen knowledge in the field.” 

The details of the presentation are as follows: 

Title: The Mouse Sodium Iodate Model Exhibits Acute Retinal Inflammation 

Authors: Karen Beets, Michaël Porcu, Tjing-Tjing Hu, Jean Feyen (Oxurion NV, Leuven, Belgium) 

Date and time: May 1st, 3:15 PM - 5:00 PM BST 

The data presented supports the use of the NaIO3 model for the investigation of age-related macular degeneration (AMD) hallmarks, a disease area where Oxurion has a number of on-going preclinical research activities. 

The poster will be available to conference attendees via the conference website. The abstract is available here.